Skip to main content
. 2021 Jul 21;218(9):e20210571. doi: 10.1084/jem.20210571

Figure 2.

Figure 2.

Tetracyclines exacerbate the activation of the ISR and affect the viability of multiple drug–tolerant states. (A) Cell growth (measured as percentage of cell confluency) of MM034 (BRAF mutant, proliferative), MM165 (NRAS mutant, invasive), MM383 (BRAF mutant, NCSC-like), and WM852 (NRAS mutant, NCSC-like) cell lines upon exposure to increasing concentrations of tigecycline for 72 h. Data are mean ± SEM of three independent experiments. ****, P < 0.0001 by Dunnett’s test. (B) Cell growth (measured as percentage of cell confluency) of MM099 (BRAF-mutant, invasive), MM165 (NRAS mutant, invasive), MM383 (BRAF-mutant, NCSC-like), and WM852 (NRAS mutant, NCSC-like) cell lines upon exposure to increasing concentrations of doxycycline for 72 h. Data are mean ± SEM of three independent experiments. ***, P < 0.001; ****, P < 0.0001 by Dunnett’s test. (C) Western blotting of a panel of different melanoma cell lines treated with DMSO (Ctrl), DT (20 and 4 nM, respectively), DTT (20 nM, 4 nM, and 20 µM respectively), tigecycline (Tige, 20 µM), or doxycycline (Doxy, 20 µM) for 72 h. Representative image of three independent experiments.